City of Hope: Longer-Term Data From SWOG S1826 Trial Confirms Nivolumab-AVD Benefit in Hodgkin Lymphoma
October 17, 2024
October 17, 2024
DUARTE, California, Oct. 17 (TNSres) -- City of Hope issued the following news release:
* * *
City of Hope(R) doctor-led research published in the New England Journal of Medicine
Adolescent and adult patients with advanced classic Hodgkin lymphoma who received initial treatment with nivolumab plus AVD chemotherapy had roughly one-half the risk of progression or death of those patients treated with a standard combination of brentuximab vedotin plus AVD
. . .
* * *
City of Hope(R) doctor-led research published in the New England Journal of Medicine
Adolescent and adult patients with advanced classic Hodgkin lymphoma who received initial treatment with nivolumab plus AVD chemotherapy had roughly one-half the risk of progression or death of those patients treated with a standard combination of brentuximab vedotin plus AVD
. . .